TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable or non-dilatable lesions, as it allows for calcium ablation or fracturing. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

The ECLIPSE study, a randomized trial, compared orbital atherectomy (OA) with balloon angioplasty (including cutting and scoring balloons) for the treatment of severely calcified lesions before drug-eluting stent (DES) implantation.

This study included patients with chronic and acute coronary syndromes (without ST elevation) and de novo lesions with severe calcification, as determined by angiography or intravascular ultrasound (IVUS)/optical coherence tomography (OCT), where plaque preparation was feasible with either therapy. 

A total of 2005 patients were enrolled across 104 US centers. Randomization was 1:1. The primary endpoints were (1) imaging analysis assessing minimal stent area (MSA) post-PCI, and (2) target vessel failure (TVF) at one year.

The average participant age was 69.9 years; 73.6% of subjects were men, and 23% had chronic kidney disease.

Read also: TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE.

In terms of the procedure, 47.6% of the orbital atherectomy group was treated via transfemoral access, 4.6% required a temporary pacemaker, 21.4% needed an extension catheter, and 42% used an OTW microcatheter or balloon. Intravascular imaging was used in 62.1% of procedures (40.3% of cases used OCT and 25.6%, IVUS).

In an analysis of the complications, there were low rates of no-reflow (0.3% vs 0.1%), type C-F dissections (6.9% vs 6.3%), and perforations (1.8% vs 1%, mostly Ellis type III). The incidence of slow flow was higher in the OA group (1.4% vs 0.4%; p=0.03). 

MSA in the most calcified region was 7.44 vs 7.05, a non-significant difference (-0.26 mm²; p=0.08). Regarding TVF at 1 year, orbital atherectomy showed an incidence of 11.5% vs 10.0% (hazard ratio [HR] 1.16; 95% confidence interval [CI] 0.87-1.54; p=0.28). 

Read also: TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting.

Regarding secondary endpoints, the OA group had higher cardiovascular mortality (p=0.005) and both groups had a similar stent thrombosis rate (0.7% vs 0.3%).

The authors concluded that routine use of orbital atherectomy did not improve MSA or reduce TVF compared with balloon PCI.

Presented by Ajay J Kirtane in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...